|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0004623,
umls-concept:C0021853,
umls-concept:C0040732,
umls-concept:C0205263,
umls-concept:C0383429,
umls-concept:C0442711,
umls-concept:C0443252,
umls-concept:C0600558,
umls-concept:C0663182,
umls-concept:C1274040,
umls-concept:C1707455
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-6-18
|
|
pubmed:abstractText |
Induction therapy with daclizumab or alemtuzumab has been recently introduced for intestinal transplantation; however, the impact of such induction therapy on bacterial infections remains to be clarified. The purpose of this study was to evaluate the impact of induction therapy on the incidence of bacterial infections and long-term patient survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1399-0012
|
|
pubmed:author |
pubmed-author:CesconMatteoM,
pubmed-author:CucchettiAlessandroA,
pubmed-author:DazziAlessandroA,
pubmed-author:Del GaudioMassimoM,
pubmed-author:ErcolaniGiorgioG,
pubmed-author:GraziGian LucaGL,
pubmed-author:KimuraTakuyaT,
pubmed-author:LaBarbaGiulianoG,
pubmed-author:LauroAugustoA,
pubmed-author:LazzarottoTizianaT,
pubmed-author:PinnaAntonio DanieleAD,
pubmed-author:PironiLorisL,
pubmed-author:RavaioliMatteoM,
pubmed-author:VivarelliMarcoM,
pubmed-author:ZanelloMatteoM,
pubmed-author:ZanfiChiaraC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
420-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19537304-Adolescent,
pubmed-meshheading:19537304-Adult,
pubmed-meshheading:19537304-Antibodies, Monoclonal,
pubmed-meshheading:19537304-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19537304-Antibodies, Neoplasm,
pubmed-meshheading:19537304-Bacterial Infections,
pubmed-meshheading:19537304-Female,
pubmed-meshheading:19537304-Humans,
pubmed-meshheading:19537304-Immunoglobulin G,
pubmed-meshheading:19537304-Immunosuppressive Agents,
pubmed-meshheading:19537304-Intestines,
pubmed-meshheading:19537304-Male,
pubmed-meshheading:19537304-Middle Aged,
pubmed-meshheading:19537304-Postoperative Complications,
pubmed-meshheading:19537304-Retrospective Studies,
pubmed-meshheading:19537304-Survival Analysis,
pubmed-meshheading:19537304-Transplantation Conditioning,
pubmed-meshheading:19537304-Young Adult
|
|
pubmed:articleTitle |
Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab.
|
|
pubmed:affiliation |
Division of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. kimutaku@pedsurg.med.osaka-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
